Suvecaltamide
CAS No. : 953778-58-0
(Synonyms: MK-8998; CX-8998; JZP385)
| Size | Price | Stock |
|---|---|---|
| 5mg | $90 | In-stock |
| 10mg | $150 | In-stock |
| 50mg | $450 | In-stock |
| 100mg | $700 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-101096 |
| M.Wt: | 380.40 |
| Formula: | C20H23F3N2O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth[1].
IC50 & Target:T-type calcium channel[1].
In Vitro: Suvecaltamide (10-1000 nM, 72 h) does not affect the inhibitory effect of Bortezomib (BTZ, HY-10227) on MM.1S, RPMI 8226, and U266B1 cells.
In Vivo: Suvecaltamide (3-30 mg/kg, once daily for 28 days, orally) reverses the peripheral nerve toxicity (CIPN) induced by Bortezomib (BTZ, HY-10227) in a rat model[1].
Suvecaltamide (30 mg/kg, once daily for 28 days, orally) reduces tumor volume in a xenograft mouse model of human multiple myeloma without affecting the anti-cancer activity of BTZ[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Suvecaltamide
- Cat. No.:
- HY-101096
- Quantity:
Your information is safe with us.